Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Hoffmann, F; Grimbacher, B; Thiel, J; Peter, HH; Belohradsky, BH, , Vivaglobin, Study, Group.
Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency.
EUR J MED RES. 2010; 15(6): 238-45.
Doi: 10.1186/2047-783x-15-6-238
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Thiel Jens
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Subcutaneous immunoglobulin (SCIG) therapy is an alternative to intravenous immunoglobulin (IVIG) therapy. METHODS: We evaluated the efficacy and safety of the SCIG Vivaglobin(formerly known as Beriglobin SC) under real-life conditions in a post-marketing observational study in 82 patients with primary or secondary antibody deficiencies. Health-related quality of life (HRQoL) was evaluated in a subset of 30 patients previously treated with IVIG (including 11 children <14 years) using the Short Form 36 (SF-36) for patients > or = 14 years of age (adults) and the Child Health Questionnaire - Parental Form 50 (CHQ-PF50) for children <14 years of age. Treatment preferences were assessed in adults. RESULTS: The mean serum immunoglobulin G (IgG) trough level during SCIG treatment (7.5 g/L) was higher than during previous IVIG treatment (6.6 g/L; p<0.01). The investigators assessed the efficacy of SCIG therapy as "excellent" in 89% of patients. No systemic adverse drug reactions were observed. Improvements by > or = 5 points were observed in 5 of 8 SF-36 subscales and in 6 of 12 CHQ-PF50 subscales. Statistically significant improvements (p< or =0.05) were observed for the SF-36 subscales of bodily pain, general health perceptions, and vitality (adults), and for the CHQ-PF50 subscales of general health perceptions, parental impact - time, parental impact - emotional, and family activities (children). Patients preferred SCIG over IVIG therapy (92%) and home therapy over therapy at the clinic/physician (83%). CONCLUSION: This study confirms that therapy with Vivaglobin at home is effective, safe, well tolerated, and improves quality of life in patients with antibody deficiency.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent - administration & dosage
- Adult - administration & dosage
- Aged - administration & dosage
- Child - administration & dosage
- Child, Preschool - administration & dosage
- Female - administration & dosage
- Health Status - administration & dosage
- Humans - administration & dosage
- Immunoglobulins - administration & dosage, blood
- Immunologic Deficiency Syndromes - immunology, physiopathology, therapy
- Immunotherapy - methods
- Infant - administration & dosage
- Injections, Subcutaneous - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- Product Surveillance, Postmarketing - administration & dosage
- Prospective Studies - administration & dosage
- Quality of Life - administration & dosage
- Severity of Illness Index - administration & dosage
- Young Adult - administration & dosage
- Find related publications in this database (Keywords)
- antibody deficiency
- subcutaneous immunoglobulin therapy
- quality of life
- children
- adults